The true value of reslizumab, recognition of which helped Teva Pharmaceutical Industries Ltd. win its 2011 bid for Cephalon Inc., moved a step closer to being more widely known Monday as the FDA accepted Teva's biologics license application (BLA) for the potential therapy.